Cervical Cancer Screening through AI and Digital Pathology

The challenge we're confronting is the urgent need for accessible, affordable, and efficient screening methods for cervical cancer, especially in regions with limited resources. Early detection holds the promise of significantly reducing mortality rates, yet current screening approaches are hindered by high costs, inaccessibility, and inefficiency, leading to delayed diagnosis and treatment initiation.

1 woman dies every 7 minutes in India from cervical cancer and timely diagnostics can lead to a 92% reduction in mortality.  Screening and diagnosis at scale remain our biggest challenges. The HPV vaccine is effective only for women below 20 Years of age and only applicable for limited virus strains.

A critical aspect contributing to this challenge is the inadequacy of existing diagnostic techniques, notably manual screening. Manual processes are labor-intensive, and prone to human error and fatigue, resulting in notable inaccuracies, particularly in settings with high patient volumes. Despite medical advancements, the widespread implementation of efficient and accurate screening methods remains a daunting task.

Globally, cervical cancer represents a significant public health burden, accounting for over 0.6 million deaths annually and comprising 11% of all female cancers. Certain regions, such as India, bear a disproportionate share of this burden, with 23% of global cervical cancer deaths. In India alone, approximately 100,000 women are diagnosed with cervical cancer each year, with a staggering 62% resulting in fatalities. These statistics underscore the critical need for scalable, cost-effective screening solutions to mitigate the devastating impact of cervical cancer.

Compounding the challenge is the limited effectiveness of preventive measures, such as the Human Papillomavirus (HPV) vaccine, which is currently only effective for women below 20 years of age and addresses a limited spectrum of virus strains. This leaves a significant portion of the female population vulnerable to the disease, particularly those outside the target age range for vaccination.

Additionally, the high cost and inaccessibility of screening methods exacerbate disparities in healthcare access, particularly in resource-limited settings where financial constraints and infrastructure challenges impede comprehensive screening programs. Consequently, many women face barriers to timely diagnosis and treatment, resulting in higher mortality rates compared to more developed regions.

Addressing this multifaceted challenge requires a comprehensive approach encompassing various strategies. Developing affordable, accessible screening solutions tailored to the specific needs of resource-limited settings is paramount. Moreover, improving diagnostic efficiency through technological innovations, can streamline the process and mitigate human error and fatigue.

Furthermore, targeted interventions focusing on high-risk populations and underserved communities must ensure equitable access to screening and treatment services. Public health campaigns aimed at raising awareness about cervical cancer prevention, early detection, and the importance of regular screening can also play a vital role in reducing the burden of the disease.

In conclusion, addressing the challenge of cervical cancer requires concerted efforts at all levels to overcome barriers to screening and diagnosis, particularly in resource-limited settings. By prioritizing the development of accessible screening solutions, improving diagnostic efficiency, and implementing targeted interventions, we can work towards reducing the devastating impact of cervical cancer on women's lives worldwide.

Vyuhaa is harnessing AI to Empower Precise Diagnoses, Accelerate Early Detection, and Save Lives. Cervical cancer poses a significant threat to women's lives, with early diagnosis being crucial for survival. Unfortunately, current detection methods are costly and often inaccessible, especially in resource-limited settings, leading to delays in diagnosis and intervention. Our solution addresses this challenge by offering a low-cost AI-enabled cancer screening model. By integrating image processing algorithms and machine learning, we provide faster, more accurate, and automated screening results, potentially saving countless lives. Moreover, the scalability of our device and AI technology opens doors to diagnosing other forms of cancer during biopsies and various histopathological diagnostics, further expanding its impact on healthcare.

Vyuhaa Meddata's cutting-edge digital pathology platform is tailored to address the urgent need for improved cervical cancer screening and diagnosis, with a focus on women aged 28-55 across South and South East Asia, including India, the United Kingdom, and the European Union. This solution is designed to directly impact the lives of individuals who face barriers to accessing traditional pathology services, particularly in regions where healthcare resources may be limited.

The device includes a High-Definition Microscope and Image Digitizer, a Digital viewer available on-screen or via Cloud, and an AI Layer for image analysis, offering end-to-end service and reducing processing costs by 70-80%.

Combining SAMD and AI in a Human-Hybrid model provides higher processing sensitivity at 10% of current costs, while our AI-enabled cervical cancer screening Hardware and SAMD reduce Pathologists' manpower costs by 90%.

Our Differentiators:

1)High-quality in-house digitization capturing images at 20x resolution.

2)AI-driven diagnostics software optimizing image viewing and providing remote accessibility.

 At the core of Vyuhaa Meddata's platform is an advanced AI-enabled system integrated with a high-resolution 20x device. This system digitizes and localizes the entire diagnostic process, from sample analysis to preliminary diagnosis. For cancer diagnosis, our state-of-the-art digitizer and inbuilt AI system identify and label abnormal cancer cells on a smear sample. Leveraging machine learning algorithms trained on a vast dataset comprising over 4000 samples collected over 2-3 years, the AI accurately identifies and labels abnormal cancer cells on smear samples, ensuring precise and reliable diagnoses.

With a specificity of around 98% and a sensitivity of 100%, the AI-enabled system virtually eliminates the risk of false positives and negatives, providing patients with accurate diagnoses promptly. This is a significant improvement over traditional manual screening methods, which are susceptible to human error, fatigue, and variability in interpretation.

Importantly, Vyuhaa Meddata's platform not only delivers precise diagnoses but also streamlines diagnostic workflows for healthcare professionals. By digitizing the entire process and integrating an intuitive on-screen viewer, the platform enables professionals to analyze critical areas on the smear efficiently. This enhances the overall efficiency of diagnostic procedures, allowing healthcare providers to deliver timely and effective care to their patients.

Our Assistive AI Technology provides a Tiled Analysis of Abnormalities enhancing sensitivity levels for pathologists.

 Furthermore, Vyuhaa Meddata's commitment to collaboration and innovation ensures that its platform remains at the forefront of diagnostic technology. By sharing technical specifications, algorithms, and software for the system and collaborating on optimizing AI algorithms, Vyuhaa Meddata empowers healthcare professionals to continuously improve diagnostic accuracy and performance.

In summary, Vyuhaa Meddata's digital pathology platform represents a significant advancement in cervical cancer screening and diagnosis, with the potential to revolutionize healthcare outcomes for women across diverse regions, including India. By providing precise, efficient, and accessible diagnostic solutions, the platform has the power to save lives, reduce the burden of cervical cancer, and advance healthcare accessibility globally.

Our team presents a formidable alliance poised to deliver the solutions you seek, backed by a wealth of expertise and leadership spanning diverse domains.

Leading our strategic endeavors is Dr. Ranjani Chakravarthy, MD Pathology, FRC Path (UK), bringing luminary status to our team. With acclaim earned for precision in cancer diagnoses and entrepreneurial spirit as Founder of C Path Labs, Dr. Ranjani's decade-long dedication to histopathology and extensive research portfolio ensure accuracy and efficacy in our diagnostic innovations.

Dhritiman Mallick, our Director at Vyuhaa Med, offers a multifaceted professional journey, enriching our team's capabilities. With pivotal roles in Deloitte Consulting LLP in Chicago and the State Bank of India in Kolkata, Dhritiman's diverse background, coupled with an MBA from IIM Bangalore, fortifies our navigation of the healthcare sector's intricate landscape.

Completing our ensemble is Krishna Mohan Reddy, also a Director at Vyuhaa Med. Armed with a Ph.D. in Metallurgy from IIT Madras and prestigious engineering degrees, Krishna's academic brilliance and executive acumen drive innovation across technical and business domains.

Last but not least, Madhusudan Chakravarthy, Director at Vyuhaa Med, brings a wealth of experience in imaging solutions and global sales initiatives. His leadership enriches our strategies with nuanced insights and seasoned direction, further enhancing our pursuit of excellence.

The solution has undergone rigorous testing, serving as a control experiment on over 5000 samples. Impressively, our sensitivity numbers have consistently hovered around 100%, showcasing the solution's robustness and reliability in detecting the targeted outcomes.

Moreover, we have successfully deployed the end-to-end solution for field studies, where its efficacy has been demonstrated in real-world settings. This hands-on experience has not only validated the solution's performance but has also generated significant word-of-mouth growth within the community.

Furthermore, our success in the field has attracted corporate sponsorships, indicating widespread recognition and support for our solution. These partnerships not only provide financial backing but also validate the value proposition of our solution in addressing critical needs.

We are applying to Solve because we are deeply passionate about addressing the pressing global health challenge posed by cervical cancer. With Vyuhaa Meddata's pioneering R&D initiative to integrate AI technologies into cervical cancer screening, targeting improved detection rates and heightened screening efficacy, we see an opportunity to make a meaningful impact in women's health. The project's dual focus on advancing technology and navigating regulatory landscapes aligns perfectly with our expertise and interests.

The project's objectives, including feasibility assessment, accuracy enhancement, prototype refinement, pilot deployments, and regulatory approvals, underscore a comprehensive approach aimed at revolutionizing cervical cancer screening. This initiative resonates with us as it tackles the critical issue of accessibility and affordability in healthcare, especially in regions like India where cervical cancer poses a significant burden.

The statistics regarding cervical cancer mortality rates and its disproportionate impact on women, particularly in regions like India, highlight the urgency of implementing effective screening methods. By leveraging AI technologies and strategic partnerships, this project has the potential to save thousands of lives annually through early detection and intervention.

Our backgrounds and skills in [relevant areas such as AI integration, healthcare innovation, regulatory compliance, etc.] uniquely position us to contribute to the success of this initiative. We are eager to collaborate with the team at Vyuhaa Meddata, utilizing our expertise to drive forward this transformative leap in women's health. Together, we can make a tangible difference in the fight against cervical cancer and improve outcomes for women worldwide.

Our R&D initiative marks a transformative leap in healthcare diagnostics, particularly in cervical screening. The hardware component, with its remarkable ability to slash image digitization costs by 70-80% in terms of fixed costs, stands as a game-changer in itself. This cost reduction, primarily attributed to hardware efficiency, enhances accessibility and affordability, addressing a critical aspect of healthcare. Beyond the cost implications, the true innovation lies in the seamless integration of our AI software with any digitized image, irrespective of its source. This includes images obtained from industry-standard devices like Hamamatsu or Phillips whole slide imaging devices. While the hardware optimizes the digitization process, it's the integration with our advanced AI software that elevates the entire diagnostic landscape.

Cervical cancer remains a significant global health challenge, particularly in low- and middle-income countries where access to screening and treatment is limited. Our team at Vyuhaa Med Data Private Limited has developed Cervi-AI, an innovative solution that leverages advanced artificial intelligence (AI) technology to revolutionize cervical cancer screening.

One of the key challenges in cervical cancer screening is the potential for human error in sample analysis. False negatives and false positives can result in missed diagnoses or unnecessary treatments, leading to significant patient harm and significantly higher follow-up and treatment costs. Cervi-AI addresses this challenge by enhancing the accuracy of screening through AI-powered analysis.

Access to cervical cancer screening is a critical determinant of health outcomes, particularly in underserved communities where screening services may be scarce or inaccessible. Cervi-AI aims to address this barrier by providing a cloud-based platform that enables pathologists to access screening tools from anywhere, at any time.

Compared to tests like Visual Acetic Acid Inspection, our technique has a sensitivity of ~100% and has significantly lower costs compared to the HPV DNA tests, thereby making screening affordable and providing higher gender equity in healthcare

Our impact goals for Cervi-AI are ambitious yet crucial in our mission to eliminate cervical cancer and human papillomavirus (HPV) globally. Our overarching goal is to ensure that every woman, regardless of geographical location or socioeconomic status, has access to high-quality cervical cancer screening through our program.

Major KPIs to be monitored:

1. Global Coverage: Cover and develop local partnerships with as many countries

2.Screening Reach: Number of screenings per day

3. Health Outcomes: Link the diagnosed condition with necessary treatments

About the Technology:

The device consists of (a) A High-Definition Digitizer (b) An On-screen viewer (Remote/On-premise) and (c) An Artificial Intelligence layer for aiding Analysis (under testing) for cervical cancer screening. 

For cancer diagnosis, the high-resolution digitizer and an inbuilt AI system identify and label abnormal cancer cells on a Cervical smear sample.

Key Features and Advancements:

1.  Tailored Image Acquisition: Our device integrates a digital scanner with robotic control, offering precise image capture for cytological samples. The microscope employs advanced focusing strategies, optimizing z-axis utilization, and ensuring seamless conversion of individual cells and groups into high-resolution Virtual Slides (VS).

2.  Optimized Resolution: Recognizing the distinct requirements of cytology slides, our device allows for scanning at higher magnifications, up to ×20 or ×40 z-stack, enhancing diagnostic accuracy for conditions like cervical-vaginal cytology.

3.  Specialized Hardware: The hardware is designed to handle various sample types, including liquid-based cytology (LBC) smears and cell blocks, ensuring a standardized approach in preparation and staining.

4.  User-Friendly Viewing and Annotation: Our device offers flexible options for viewing and managing VS, and compatibility for annotation. Image viewers provide a seamless experience, allowing pathologists to annotate, export, and discuss images in real time, fostering collaborative diagnostics.

5.  AI Integration for Cervical Cancer Diagnosis: The WSI system is can be integrated with AI algorithms specifically trained for cervical cancer diagnosis. The AI component enhances diagnostic accuracy, providing pathologists with valuable insights for more informed decision-making.

6. Current Technical specifications for AI efficacy:

Process Details and Current State: 

The Proposed Intervention uses digital pathology and AI and reduces
the time of diagnosis to only a few hours 

Our technology simplifies whole slide imaging and can be used to process slides from outside India by our EU-accredited pathologists.

The team consists of 5 members:

Krishna Mohan Reddy: Technical Director

Dr. Ranjani Chakravarthy: Director, Clinical Operations

Madhusudan Chakravarthy: Director, Business Development

Dhritiman Mallick: Director, Operations and Strategy

1.5 years

At Vyuhaa Med Data Private Limited, we recognize the importance of fostering a diverse, equitable, and inclusive workplace culture. We are committed to ensuring that our team reflects the diversity of the communities we serve and that all team members have equal opportunities for growth and success. Here's how we ensure diversity, minimize barriers to opportunity, and promote inclusivity within our organization:

1. Recruitment and Hiring Practices: We actively seek out candidates from diverse backgrounds and underrepresented groups to ensure a broad range of perspectives and experiences within our team. Our recruitment process is designed to minimize biases and create a level playing field for all applicants. We also partner with organizations and initiatives that focus on diversity and inclusion in the workplace to attract a diverse talent pool.

2. Equal Opportunities for Growth: We believe in providing equal opportunities for career advancement and professional development to all team members. We offer training programs, mentorship opportunities, and career pathing initiatives to support the growth and advancement of every employee, regardless of their background or identity. Promotions and leadership positions are based on merit, skills, and qualifications, rather than factors such as gender, race, or ethnicity.

3. Inclusive Workplace Policies: We have established inclusive workplace policies and practices that promote fairness, respect, and dignity for all employees. Our policies address issues such as harassment, discrimination, and unconscious bias, and we provide training and resources to ensure that all team members understand their rights and responsibilities.

Our plan for achieving financial sustainability revolves around strategic partnerships, competitive pricing strategies, and delivering high-quality products and services that meet the needs of our customers. Here's how we're executing our plan and evidence of our success so far:

1. Partnerships with Non-Profit Organizations: By partnering with non-profit organizations, we not only fulfill our social responsibility but also expand our reach and access to underserved communities. These partnerships allow us to deliver our products and services at reasonable profit margins while making a positive impact on public health.

2. Competitive Pricing Strategy: In the B2B model, we have implemented a competitive pricing strategy that offers our products and services at lower prices than market leaders. This approach aims to attract customers seeking cost-effective solutions without compromising on quality.

3. Positive Market Response: Both our products and services have garnered a positive response from the market, indicating strong demand and customer satisfaction. Evidence of success includes customer testimonials, reviews, and case studies highlighting the benefits and effectiveness of our solutions.
   

4. Scalability and Market Potential: With the right support and resources, we have the potential to capture a significant market share in our industry. The operations are modular and scalable with low investment costs.